We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going ...

Biotechnology company Moderna (NASDAQ:MRNA) in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other ...

As bad as it may look on the charts, Moderna’s (NASDAQ: MRNA) post-COVID let-down and market reset are over. The company ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...

Q4 2024 Earnings Call Transcript February 14, 2025 Moderna, Inc. misses on earnings expectations. Reported EPS is $-2.91 EPS, ...

Below is Validea's guru fundamental report for MODERNA INC (MRNA). Of the 22 guru strategies we follow, MRNA rates highest using our Value Investor model based on the published strategy of ...

CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company specializing in mRNA-based therapies and vaccines with a market ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

For MRNA (NASDAQ:MRNA), we notice a put option trade that happens to be bullish, expiring in 336 day(s) on January 16, 2026. This event was a transfer of 500 contract(s) at a $20.00 strike.

Investors in Moderna Inc (Symbol: MRNA) saw new options become available today, for the April 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRNA ...